Updated:
Vividion Therapeutics
We are bringing more disease-causing targets within the reach of small molecule therapeutics to transform care for patients with devastating diseases not
Vividion Therapeutics
We are bringing more disease-causing targets within the reach of small molecule therapeutics to transform care for patients with devastating diseases not
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Sector focus
Frequently asked questions
What is VVD-214 and why does its mechanism matter?
VVD-214 is a covalent allosteric inhibitor of the WRN helicase. WRN is a synthetic-lethal target in microsatellite-instability-high tumors, meaning cancer cells that rely on WRN for survival cannot compensate when the protein is blocked. Vividion published the discovery and preclinical characterization of VVD-214 in January 2026, confirming its clinical-stage advancement (per Journal of Medicinal Chemistry, 2026). Allosteric inhibition offers a selectivity advantage over orthosteric approaches, reducing off-target toxicity in a target class where ATP-competitive inhibitors have historically struggled.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: